Why the study?
Atrial arrhythmias are common in diabetes mellitus and carry substantial mortality and morbidity despite advances in treatment, while clinical trial data suggest SGLT2 inhibitors may prevent AF and AFl.
Do sodium-glucose cotransporter-2 inhibitors prevent the occurrence of atrial fibrillation and atrial flutter in patients with diabetes mellitus?
Do sodium-glucose cotransporter-2 inhibitors prevent the occurrence of atrial fibrillation and atrial flutter in patients with diabetes mellitus?
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors may have a protective effect against the development of atrial fibrillation and atrial flutter in patients with diabetes mellitus.
Atrial arrhythmias are common in patients with diabetes mellitus (DM), and despite recent advances in pharmaceutical and invasive treatments, atrial fibrillation (AF) and atrial flutter (AFl) are still associated with substantial mortality and morbidity. Clinical trial data imply a protective effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on the occurrence of AF and AFl. This review summarizes the state of knowledge regarding DM-mediated mechanisms responsible for AF genesis and recurrence but also discusses the recent data from experimental studies, published trials and metanalyses.
No takes yet. Share an insight, caveat, or question.
Karamichalakis et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: